top of page
PIQUR
OFFICIAL TITLE: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTRE PHASE 1/ 2B STUDY INVESTIGATING SAFETY AND EFFICACY OF PQR309 AND ERIBULINCOMBINATION IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2 NEGATIVE AND TRIPLE-NEGATIVE BREAST CANCER.
SCIENTIFIC IMPACT
CLINICAL TRIAL DETAILS
THIS STUDY IS AN OPEN-LABEL,NON RANDOMIZED, MULTI-CENTER, PHASE 1/2B (DOSE ESCALATION FOLLOWED BY EXPANSION PART) STUDY EVALUATING CLINICAL SAFETY, EFFICACY AND PHARMACOKINETICS OF PQR309 IN COMBINATION WITH STANDARD DOSE OF ERIBULIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE (ESCALATION PART) AND TRIPLE NEGATIVE BREAST CANCER (EXPANSION PART).
LEGAL STUDY SPONSOR IS PIQUR THERAPEUTICS AG
PIQUR AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
BREAST
I/IIb
43
6
Spain, UK
N
SITES
COUNTRY
STATUS
Recruitment closed
SABCS 2016 – DOWNLOAD THE POSTER
PIQUR SITES
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Instituto Valenciano de Oncología (IVO)
SPAIN
Hospital Universitari Vall D'Hebron
SPAIN
Institut Català d' Oncologia L'Hospitalet (ICO)
UK
Churchill Hospital, Oxford
UK
Barts Cancer Institute
bottom of page